These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33481252)

  • 21. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of echinocandin administration on hemodynamic parameters in medical intensive care unit patients: a single center prospective study.
    Lahmer T; Schnappauf C; Messer M; Rasch S; Fekecs L; Beitz A; Eser S; Schmid RM; Huber W
    Infection; 2015 Dec; 43(6):723-7. PubMed ID: 26259643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
    Sinnollareddy MG; Roberts JA; Lipman J; Akova M; Bassetti M; De Waele JJ; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Dimopoulos G;
    Crit Care; 2015 Feb; 19(1):33. PubMed ID: 25888060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
    van der Geest PJ; Rijnders BJ; Vonk AG; Groeneveld AB
    Mycoses; 2016 Mar; 59(3):179-85. PubMed ID: 26707572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
    Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
    J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
    Liu P; Ruhnke M; Meersseman W; Paiva JA; Kantecki M; Damle B
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1672-6. PubMed ID: 23335738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study.
    Micek ST; Arnold H; Juang P; Hampton N; McKenzie M; Scolarici M; Kollef M
    Clin Ther; 2014 Sep; 36(9):1226-32. PubMed ID: 25064625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for isolation of fluconazole and echinocandin non-susceptible
    Papadimitriou-Olivgeris M; Spiliopoulou A; Fligou F; Tsiata E; Kolonitsiou F; Nikolopoulou A; Papamichail C; Spiliopoulou I; Marangos M; Christofidou M
    J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34431765
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy.
    Garnacho-Montero J; Díaz-Martín A; Cayuela-Dominguez A
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S137-41. PubMed ID: 19013338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010].
    Olaechea-Astigarraga PM; Alvarez-Lerma F; Palomar-Martínez M; Insausti-Ordeñana J; López-Pueyo MJ; Seijas-Betolaza I; Otal-Entraigas JJ; Gimeno-Costa R; Gracia-Arnillas MP;
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):435-40. PubMed ID: 22463989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of micafungin and anidulafungin in the treatment of systemic fungal infections: applications and patents for two novel echinocandins.
    Hinske LC; Weis F; Heyn J; Hinske P; Beiras-Fernandez A
    Recent Pat Antiinfect Drug Discov; 2012 Apr; 7(1):1-7. PubMed ID: 22044354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of anidulafungin in critically ill patients].
    Borges Sá M; Garnacho Montero J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():35-43. PubMed ID: 19572433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.